DEVELOPMENT OF MULTIPARTICULATE FORMULATION AND EVALUATION OF COLON TARGETED DRUG DELIVERY SYSTEM OF CIPROFLOXACIN: IN VIVO STUDY WITH INDUCED  COLITIS MODEL IN RATS by Rangari, Nalanda Tulsiram & Puranik, Prashant K
Vol 10, Issue 1, 2017
Online - 2455-3891 
Print - 0974-2441
DEVELOPMENT OF MULTIPARTICULATE FORMULATION AND EVALUATION OF COLON 
TARGETED DRUG DELIVERY SYSTEM OF CIPROFLOXACIN: IN VIVO STUDY WITH INDUCED 
COLITIS MODEL IN RATS
NALANDA TULSIRAM RANGARI1*, PRASHANT K PURANIK2
1Department of Pharmaceutics, Swami Ramanand Teerth Marathwada University, Nanded, Maharashtra, India. 2Department of 
Pharmaceutical Sciences, RTM Nagpur University, Maharashtra, India. Email: nalanda.rangari@gmail.com
Received: 11 August 2016, Revised and Accepted: 21 September 2016
 ABSTRACT
Objective: The objective of this research work was to develop a multiparticulate containing chitosan and guar gum for the treatment of ulcerative 
colitis.
Method: Method for the formulation of multiparticulate was done by extrusion-spheronization method using Eudragit L-100 and Eudragit S-100 as a 
coating solution and ciprofloxacin as a model drug.
Result: Result from preliminary trial batches was previously assessed for physicochemical characterization, in vitro release, ex vivo mucoadhesion 
study, swelling studies, and in vivo evaluation and showed that the formulations appeared to be a good candidate to deliver the drug to the colon. 
Box-Behnken design was used to statistically optimize the formulation parameters and evaluate the main effects, interaction effects, and quadratic 
effects of the process parameters of enteric-coated multiparticulate on drug polymer ratio and coat composition. In this work, the effectiveness 
of optimized batch (C4) in the treatment of inflammatory bowel disease was evaluated. Experimentally, colitis was induced by rectal instillation 
of 2, 4, 6, trinitrobenzene sulfonic acid into male Wistar rats. The histological evaluations were done as inflammatory indices. In vivo gamma 
scintigraphy studies of multiparticulate without a drug demonstrate degradation of multiparticulate whenever they reach colon.
Conclusion: The conclusion from results of studies such as gamma scintigraphy and histological study of optimized formulation (C4) clearly indicates 
that there is a great potential in delivery of ciprofloxacin to the colonic region. The animals treated with ciprofloxacin (C4) formulation had an 
improvement in pathology and may be useful for the treatment of inflammatory bowel disease.
Keywords: Chitosan, Guar gum, Ciprofloxacin, Gamma scintigraphy, Histology, Ulcerative colitis, Box-Behnken design.
INTRODUCTION
The colon is an ideal site for protein and peptide absorption. Acidic and 
enzymatic degradations are major obstacles in the oral administration 
of peptide drugs, but by targeting to the colon, the proteolysis can be 
minimized. Colon targeting had application in several therapeutic areas 
such as colon cancer, ulcerative colitis, irritable bowel syndrome, or 
the administration of drugs that are adversely affected by the upper 
gastrointestinal tract (GIT). There has been considerable research in 
the design of colonic delivery systems and targeting has been achieved 
by several ways. The primary approaches to the colonic delivery of 
the drugs included prodrugs, coating with pH-sensitive and time-
dependent polymers. Eudragit L-100 and Eudragit S-100 are used as 
an enteric-coating material to keep the multiparticulates intact and 
not to release the drug in stomach and or upper intestine. Natural 
polysaccharides such as pectin, chitosan, xylan, and guar gum are not 
digested in the human stomach or small intestine but are degraded in 
the colon by resident bacteria. Chitosan is a cationic natural copolymer 
of glucosamine, obtained from the deacetylation of chitin, which is the 
second most abundant polysaccharide after cellulose in the world. It has 
been widely used in several pharmaceutical formulations as controlled 
release carrier systems such as beads, gels, films, sponges, and 
multiparticulates for its many unique properties such as low toxicity, 
biocompatibility, and biodegradability chitin is a polysaccharide 
composed of β-(1-4) linked N-acetyl-D-glucosamine unit. Chitosan is a 
weak base and is insoluble in water and organic solvents; however, it is 
soluble in dilute aqueous acidic solution (pH<6.5), which can convert the 
glucosamine unit to R-NH+ 3. In pharmaceutical formulations, chitosan 
is used as a vehicle for directly compressed tablets disintegrating, 
binding, and granulating agent [1-3].
Ciprofloxacin is a quinolone carboxylic acid derivative with an extensive 
antibacterial spectrum of activity. Ciprofloxacin is an antibiotic useful 
for the treatment of a number of bacterial infections. It is a second-
generation fluoroquinolone. Ciprofloxacin and other fluoroquinolones 
are valued for this broad spectrum of activity, excellent tissue penetration, 
and for their availability in both oral and intravenous formulations. The 
absolute bioavailability is approximately 70% with no substantial loss 
by first pass metabolism. The drug has been shown to be active in most 
strains of the following microorganisms both in vitro and in clinical 
infections: Aerobic Gram-positive microorganisms - Enterococcus 
faecalis, Streptococcus pneumonia, Streptococcus pyrogenes, 
Staphylococcus saprophyticus, and Staphylococcus aureus; aerobic 
Gram-negative microorganisms - Enterobacter cloacae, Escherichia 
coli, Pseudomonas aeruginosa, Salmonella typhi, Klebsiella pneumonia, 
Neisseria gonorrhoeae, and Shigella sonnei.
T he rational of present investigation was to target the enteric-coated 
multiparticulate of ciprofloxacin to colon for the successful treatment of 
ulcerative colitis induced by rectal instillation of 2, 4, 6, trinitrobenzene 
sulfonic acid into male Wistar rats. The novelty behind the formulation 
was degradation of multiparticulate whenever they reach the colon 




Chitosan of medium molecular weight, ciprofloxacin, and guar gum 
was obtained from Space Lab (Nasik, Maharashtra, India). 2, 4, 6, 
trinitrobenzene sulfonic acid was purchased from Vishal Chem 
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(Mumbai, Maharashtra, India). Eudragit L-100 and Eudragit S-100 were 
obtained as a gift sample from Concept Pharmaceutical (Aurangabad, 
Maharashtra, India).
Preparation of multiparticulate of ciprofloxacin
The multiparticulate of ciprofloxacin was prepared using the extrusion-
spheronization technique (RIMEK, Kalweka HD410AC, Gujarat, India). 
Briefly, chitosan and guar gum were first mixed using a laboratory blender 
(LB100 Laboratory Blender; REMI, Mumbai, India) for 10 minutes, and 
deionized water was added with further mixing (15 minutes) for the 
production of wet mass. The wet mass was extruded with an extruder 
(sieve opening 1 mm; screen thickness 3.25 mm; 15 rpm; extrudate cut off 
at a length of approximately 2-3 mm) and spheronization of the extrudate 
in a spheronizer (spheronization speed 2200 rpm; spheronization time 
about 5 minutes). Multiparticulate in the size fraction 1.1-1.4 mm (N75% 
yield in this size range) was used in the subsequent studies. The resultant 
multiparticulate was dried in a fluidized bed dryer at 30°C until the loss 
on drying, was <2.5 wt% (Labultima, LU222 Advanced, Mumbai, India) 
Table 1 shows trial batches [4,5].
Coating of multiparticulate
The enteric coating was done using conventional coating pan. 10% and 
15% (w/w) solutions of polymethacrylates (Eudragit L100 and Eudragit 
S100) were prepared in isopropyl alcohol:water (9:1) mixture. The ratio 
of Eudragit S100:Eudragit L100 was 1:1; the enteric coating was done 
using conventional coating pan, and solutions of polymethacrylates 
were prepared in isopropyl alcohol:water (9:1) mixture. The ratio of 
Eudragit S100:Eudragit L100 was 1:1. The solution was plasticized with 
castor oil (20%, w/w, with respect to dry polymer), titanium dioxide 
(0.05% w/v), and then, talc was added as glidant (5%, w/w, related 
to dry polymer). The enteric-coating dispersion was passed through a 
0.3 mm sieve before use. Throughout the coating process, the coating 
dispersion was stirred using a magnetic stirrer. The parameters of 
the film-coating process were as follows: Pan rotating speed 20 rpm; 
atomizing air pressure 2 bar; inlet air temperature 60-70°C; outlet 
air temperature 35-40°C; multiparticulate bed temperature 38°C; 
the coating solution was applied through a 1.1 mm spray nozzle. The 
film-coated multiparticulate was not removed from the pan until the 
complete weight gain was achieved. All the multiparticulate was stored 
in a vacuum desiccator at room temperature until used. A series of 
coated products with different film thickness was produced, quantified 
by the percentage total weight gain, by varying the amount of coating 
solutions sprayed.
Exper imental design for optimization
Response surface methodology (RSM) is a widely practiced approach 
in the development and optimization of drug delivery devices. 
Based on the principle of design of experiments, the methodology 
encompasses the use of various types of experimental designs, 
generation of polynomial equations, and mapping of the response 
over the experimental domain to determine the optimum processing 
variables [6]. The technique requires minimum experimentation and 
time, thus proving to be far more effective and cost-effective than the 
conventional methods of formulating dosage forms. Box-Behnken 
design was used to statistically optimize the formulation parameters 
and evaluate the main effects, interaction effects, and quadratic effects 
of the process parameters of enteric-coated multiparticulate on drug 
polymer ratio and coat composition. A 3-factor, 3-level design was used 
to explore the quadratic and linear response surfaces using Design 
Expert Software (Version 9.0.1, Stat-Ease Inc., and Minneapolis, MN). 
Statistical validity of the polynomials was established on the basis of 
analysis of variance (ANOVA) provision in the Design Expert Software. 
Level of significance was considered at p<0.05. The best-fitting 
mathematical model was selected based on the comparison of several 
statistical parameters, including the coefficient of variation (CV), the 
multiple correlation coefficient (R2), the adjusted multiple correlation 
coefficient (adjusted R2), and the predicted residual sum of squares 
(PRESS), provided by the software. PRESS indicates how well the model 
fits the data, and for the chosen model, it should be small relative to 
the other models under consideration. The 3D response surface 
graphs and the 2D contour plots as generated by the Design Expert 
Software. These plots are very useful to see interaction effects of the 
factors on responses. Experimental design was done for optimization of 
polymer and optimization of coat composition (Eudragit S and L 100). 
Box-Behnken design was applied in the present study by considering 
chitosan, guar gum, and coat composition (Eudragit S and L 100) as 
independent variables and entrapment efficiency, mucoadhesion, % 
drug release at 9, 12, 18, and 24 hr as dependent variables (Table 2).
Table 1: Preliminary trial batches of multiparticulate
















Coat composition: a=10, b=15%
Table 2: Factorial batches of ciprofloxacin
Batch code Variable level A Variable level B Variable level C Chitosan (mg) Guar gum (mg) Coat composition (%)
C1 1 −1 0 170 80 12.5
C2 1 1 0 170 170 12.5
C3 0 1 −1 130 170 10
C4 1 0 −1 170 130 10
C5 0 0 0 130 130 12.5
C6 0 0 0 130 130 12.5
C7 1 0 1 170 130 15
C8 −1 0 1 80 130 15
C9 0 0 0 130 130 12.5
C10 0 0 0 130 130 12.5
C11 −1 1 0 80 170 12.5
C12 0 −1 1 130 80 15
C13 0 1 1 130 170 15
C14 0 0 0 130 130 12.5
C15 −1 0 −1 80 130 10
C16 −1 −1 0 80 80 12.5
C17 0 −1 −1 130 80 10
Variable level: Low (−1), Medium (0), High (1)
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Table 2 shows the different variables and its levels used in the 
optimization design. Using these variables at different three levels, the 
trials were designed.
Evaluation of multiparticulate
Micromeritics studies of multiparticulates
The m ultiparticulates were characterized by their micromeritics 
properties such as particle size, bulk density, tapped density, Carr’s 
compressibility index, Hausner ratio, and flow property.
Swelling studies of multiparticulates
A known weight (100 mg) of various multiparticulates without drug 
was placed in phosphate buffer, pH 7.4, and allowed to swell for the 
required period at 37±0.5°C using the USP dissolution apparatus with 
the dissolution basket assembly at 100 rpm. The multiparticulate 
particles were periodically removed blotted with filter paper and their 
changes in weight were measured during the swelling until equilibrium 
was attained. Finally, the weight of the swollen multiparticulate 
particles was recorded after a time period of 4 hrs, and the swelling 
ratio (SR) was then calculated from the formula:
SR=(We−W0)/W0
Where, W0 “is the initial weight of the dry multiparticulate” and We “is 
the weight of the swollen multiparticulate at equilibrium swelling” in 
the media. Each experiment was repeated three times, and the average 
value/standard deviation (SD) was taken as the SR value.
Percentage yield (i.e. recovery) of multiparticulates formed
The percentage yield of multiparticulate was determined by weighing 
after drying. The measured weight of prepared multiparticulates was 
divided by the total amount of all the nonvolatile components used 
for the preparation of the multiparticulates, which gave the total 
percentage yield of multiparticulates.
% Yield= (Actual weight of product/Total weight of excipient and 
drug)×100
Drug content determination
Multiparticulates equivalent to 250 mg of the drug ciprofloxacin were 
taken for evaluation. The amount of drug entrapped was estimated 
by crushing the multiparticulates and extracting in 100 ml methanol. 
After 24 hr, the extract was transferred to a 100 ml volumetric flask 
and the volume was made up using methanol. The solution was 
filtered and the absorbance was measured after suitable dilution 
spectrophotometrically at 281 nm against methanol as a blank.
The amount of drug entrapped in the multiparticulates was calculated 
by the following formula:
= ×
Calculated drug concentration
% Drug entrapment 100
Theoretical drug concentration
Placebo multip articulates were used as reference.
Ex vivo mucoadhesion study
The mucoadhesive property of the multiparticulate is evaluated on 
goat’s intestinal mucosa by using phosphate buffer, as per monograph. 
Weighed microspheres were spread onto wet rinsed tissue specimen, 
and immediately thereafter, the slides are hung onto the arm of a USP 
tablet disintegrating test machine with suitable support at 37°C. The 
weight of microspheres leached out at different intervals is measured. 
The % mucoadhesion is calculated by the following equation:
% Mucoadhesion=Wa−W1/Wa×100
Where, Wa is the weight of multiparticulate applied, and W1 is the 
weight of multiparticulate leached out.
Dissolution test (in vitro drug release) of multiparticulates
In vitro dissolution test was conducted in USP 2 apparatus at 50 rpm 
and a temperature of 37±0.5°C. Sampling was done at predetermined 
time intervals and the same were estimated for drug content after 
suitable dilution using double beam UV-VIS spectrophotometer. Initial 
drug release studies were conducted in 900 ml of 0.1N HCl for 2 hrs 
followed by 900 ml of 6.8 potassium phosphate buffer solution for 
next 3 hrs. Then, 900 ml of 7.4 potassium phosphate buffer solution 
for rest of the time. Samples were filtered and assayed by ultraviolet 
spectrophotometry at 281 nm. The concentration of each sample was 
determined from a predetermined calibration curve for ciprofloxacin.
Optimization
On the basis of evaluation parameters such as entrapment efficiency, 
percent yield, swelling studies, ex vivo mucoadhesion, and dissolution 
characteristics of the factorial batches of ciprofloxacin, which has 
shown the best results were optimized and selected for formulation 
of final dosage form (capsule) and advanced studies such as X-ray 
diffraction (XRD), differential scanning colorimeter (DSC), scanning 
electron microscopy (SEM), in vivo studies (Gamma scintigraphy), and 
histopathological evaluation was performed.
Advanced studies on optimized batch of multiparticulates
XRD study
XRD measurements were made using Make: BRUKER, Germany, 
Model: D8 Advance, Source: 2.2 KW Cu Anode, Dermic X-ray tube, 
Detector: Lynux Eye Detector, Beta Filter: Ni Filter Sample Holder: Zero 
Background and PMMA. The X-ray generator was operated at 40 kV and 
30 mA, using the Cu K line at 1.540600 Å as the radiation source.
Each powdered specimen was packed in a specimen holder made of 
glass. In setting up the specimen and apparatus, coplanarity of the 
specimen surface with the specimen holder surface and the setting of 
the specimen holder at the position of symmetric reflection geometry 
were ensured. The powders were passed through a 100 mesh sieve and 
were placed into the sample holder by the side drift technique. The 
holder consisted of a central cavity. To prepare a sample for analysis, 
a glass slide was clipped to the top face of the sample holder so as 
to form a wall. The powder sample was filled into the holder, gently 
tapped and used for XRD measurement. 10 mg of each sample was 
scanned at 25°C from 10-70° and in step size of 0.019724 and count 
time of 46.5 seconds, using an automatic divergence slit assembly and 
a proportional detector. Relative intensities were read from the strip 
charts and corrected to fixed slit values.
DSC studies of optimized multiparticulates
Thermogram of samples was obtained by a Perkin-Elmer DSC. Samples 
of 10 mg were accurately weighed into aluminum pans and then 
hermetically sealed with aluminum lids. The thermogram of samples 
was obtained at a scanning rate of 10°C/minutes over a temperature 
range of 40-390°C.
Morphological study using SEM
The surface topography of the coated (optimized) multiparticulate 
examined under an FEI-Philips XL-30 Analytical Electron Microscope 
(IIT, Pawai). The sample was loaded on copper sample holder and 
sputter coated with platinum.
In vivo gamma scintigraphy study
The experiment was conducted in the laboratory of “Spect Lab Nuclear 
Medicine,” Pune. The study reported here adheres to the principle of 
laboratory animal care and was approved by the Institutional Ethical 
Committee permitted by the IAEC with the CPCSEA registration number 
AVCOP/IAEC/1153/01. Wistar rats, weighing 200-250 g, were taken for 
the study. The animals fasted for 12 hrs before the commencement of 
the experiment. Radiolabeled (>90%) multiparticulates (50 mg) of the 
formulation without drug was administered orally to the animals with 
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the help of feeding tube, followed by sufficient volume of drinking water. 
All four legs of rat were tied over a piece of plywood, and the location 
of the formulation in GI tract was monitored keeping the subject in 
front of a gamma camera. The total radiation dosimetry for each rat 
was 0.1 mSv. Scintigraphy image was captured using a Siemens E-Cam 
gamma camera fitted with a LEHR collimator. The image schedule was 
as follows: Immediate, 15, 30, 60, 120, 180, 240, 300, and 360 minutes. 
During the gamma scintigraphy scanning, the animals were freed and 
allowed to move and carry out normal activity [7,8].
Histopathology evaluation
The study reported here adheres to the principle of laboratory animal 
care and was approved by the Institutional Ethical Committee AVCOP/
IAEC/1153/01.
Induction of inflammation by 2, 4, 6, trinitrobenzene sulfonic acid
These studies were carried out on Wistar male rats aged 8-12 weeks 
and weighing 230-250 g. Animals were housed in an air-conditioned 
room at 22±3°C, 55±5% humidity, 12 hrs light/dark cycles, and allowed 
free access to water and laboratory chow for the duration of the 
studies. To induce the model of chronic inflammation in the rat colon, 
the method described by Morris et al. (1989) was followed with some 
modification. Briefly, rats were arbitrarily separated into treatment 
groups, fasted for 48 hrs with free access to water and then anesthetized 
with ketamine [9].
In our studies, 0.5 ml of solution of 2, 4, 6, trinitrobenzene sulfonic acid 
at a dosage of 81 mg/kg-body weight dissolved in 50% ethanol (v/v) 
was inserted rectally into the colon using graduated rubber canula 
such that the tip was 8 cm proximal to the anus was instilled into the 
lumen of the colon through rubber probe for 12 weeks consecutively. 
On 12th week, the rat was sacrificed with overdose of anesthesia. The 
development of inflammation was evaluated with respect to colon/
body weight ratio and histological changes.
Experimental design
A total of 12 Wistar male rats were used in this study. The rats were 
randomized and divided into three groups of four animals each.
• Group I: Vehicle control (normal saline)
• Group II: Disease control (2, 4, 6, trinitrobenzene sulfonic acid 
81 mg/kg-body weight)
• Group III: Disease Group II+cipro loxacin multiparticulate 
(250 mg/kg/day).
The multiparticulate of 250 mg/kg/day of ciprofloxacin (Group III) 
calculated from the dose from humans (70 kg) (Sandborn and Hanaure, 
2003) were also administered by oral gavage once a day for 3 days in the 
period when inflammation developed in colon area after 12th week [10-12].
Histopathological study
The tissue sample was appropriately trimmed and washed under 
running water and processed in different grades of isopropanol, passed 
through xylene clearance, and molten paraffin. Paraffin blocks were 
prepared, 3-5 μ thick section from each block were cut and stained 
with the hematoxylin and eosin stain [13]. After mounting with 
DPX mountant, the slides were cleaned and evaluated under a light 
microscope.
RESULT AND DISCUSSION
Assay was performed to analyze the percentage purity of ciprofloxacin 
and was found to be 98.82% pure. Appropriate dilutions were prepared 
for drug from the standard stock solution and scanned in the spectrum 
mode from 400 nm to 200 nm. Ciprofloxacin showed absorbance 
maxima at 281 nm (Fig. 1).
Selection of analytical concentration ranges
From the standard stock solution of ciprofloxacin, appropriate aliquots 
were pipetted out into 10 ml volumetric flasks and dilutions were made 
with methanol to obtain working standard solutions of concentrations 
3-18 μg/ml. Absorbance for these solutions was measured at 281 nm 
(Table 3), and a calibration curve of absorbance against concentration 
was plotted (Fig. 2).
Evaluation for multiparticulate
Micromeritics studies of trial batches of multiparticulate
The various batches (trial and factorial) have the average particle size 
in the range of 1-1.5 mm for the drug ciprofloxacin. The particle size 
of multiparticulate varies with composition of polymer added in the 
formulation. The chitosan concentration, its molecular weight, and its 
viscosity affect the size range of multiparticulate. The decrease in chitosan 
concentration decreases the size of multiparticulate. The tapped density 
value ranged from 0.49 to 0.55 g/cm3 for all batches. The bulk density 
value ranged from 0.4 to 0.53 g/cm3. All formulation showed good 
flowability as expressed in terms of angle of repose and was found within 
Table 3: Summary of results of regression analysis for responses R1 to R6
Responses Models R2 Adjusted R2 Predicted R2 Adequate precision SD %CV PRESS
R1 Quadratic 0.9354 0.8523 −0.0322 8.5540 3.1098 4.3066 1081.75
R2 Quadratic 0.9294 0.8386 −0.1287 13.0011 2.0794 2.4370 483.96
R3 Quadratic 0.9039 0.7805 −0.5355 9.7748 2.5858 3.6804 748.67
R4 Quadratic 0.9818 0.9584 0.7117 22.7012 1.0817 1.3835 129.75
R5 Quadratic 0.9947 0.9879 0.9160 41.2671 0.3429 0.4049 13.10
R6 Quadratic 0.9574 0.9028 0.3461 12.0802 1.0841 1.1880 126.52
SD: Standard deviation, CV: Coefficient of variation, PRESS: Predicted residual sum of squares
Fig. 1: Ultraviolet spectrum of ciprofloxacin
Fig. 2: Calibration curve of ciprofloxacin
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the range of 25-35°, which is an appreciable limit for multiparticulate to 
show flow property while formulating in the dosage form (Tables 4 and 5).
Swelling studies of multiparticulate of ciprofloxacin
Swelling index was calculated with respect to time. Swelling index 
increased with weight gain by the multiparticulate was increased 
proportionally with the rate of hydration. Multiparticulate swelling is 
influenced by the environmental pH, being generally greater at lower 
rather than higher pH value.
The SR of batch C5a was found to be high as compared to other 
formulation (Table 6). This might be due to increase in concentration 
of chitosan in the formulation. Initially, all the batches swell slowly but 
achieve maximum swelling among other concentrations (Fig. 3).
Swelling studies of multiparticulate of factorial batches
The SR of factorial batch of ciprofloxacin C1, C2, C4, and C7 was found 
to be high as compared to other formulation among this four batches; 
batch C4 shows maximum swelling, i.e. 1.81±0.05 (Table 7). This might 
be due to increase in concentration of chitosan in the formulation. 
Initially, all the batches swell slowly but achieve maximum swelling 
among other concentrations (Fig. 4).
Percentage yield of multiparticulate formed of ciprofloxacin
The prepared multiparticulate gives good percentage yield. The 
percentage yield of multiparticulate determined by weighing after 
drying. The maximum percentage yield was found for trial batches C3a, 
C5a, C3b, and C5b and was found to be 92.58±1.14%, 95.32±0.45%, 
92.55±2.12%, and 94.30±2.13%, respectively (Table 8 and Fig. 5).
Table 4: Analysis of variance for response R1 (entrapment efficiency)
Source Sum of squares Df Mean square F value p value P>F Significance
Model 980.2986 9 108.9220 11.2627 0.002132 Significant
A-CH 0.03645 1 0.0364 0.003768996 0.9527
B-GG 43.0128 1 43.0128 4.447602611 0.0729
C-CC 0.0946 1 0.0946 0.009783104 0.9239
AB 37.3321 1 37.3321 3.860206663 0.0901
AC 0.1024 1 0.1024 0.010588345 0.9209
BC 0.1332 1 0.1332 0.013775706 0.9098
A2 22.6871 1 22.6871 2.345893841 0.1694
B2 796.1973 1 796.1973 82.32824867 4.05E-05
C2 68.7650 1 68.7650 7.110431499 0.0321
Residual 67.6970 7 9.6710
Lack of fit 67.6002 3 22.5334 931.1332645 3.83E-06 Significant
Pure error 0.0968 4 0.0242 11.26273892 0.0021
Correlation total 1047.995694 16
Table 5: Analysis of variance for response R2 (mucoadhesion)
Source Sum of squares df Mean square F value p value P>F Significance
Model 398.4785 9 44.27539 10.23925 0.00286 Significant
A-CH 242 1 242 55.96558 0.00014
B-GG 47.97101 1 47.97101 11.09391 0.012578
C-CC 3.419113 1 3.419113 0.790713 0.403406
AB 43.0336 1 43.0336 9.952067 0.016047
AC 3.3856 1 3.3856 0.782963 0.405603
BC 0.416025 1 0.416025 0.096211 0.765456
A2 21.27318 1 21.27318 4.919693 0.062057
B2 31.9638 1 31.9638 7.392035 0.029816
C2 4.083084 1 4.083084 0.944265 0.363556
Residual 30.26861 7 4.324086
Lack of fit 30.24573 3 10.08191 1762.571 1.07E-06 Significant
Pure error 0.02288 4 0.00572
Correlation total 428.7472 16
Table 6: Analysis of variance for response R3 (drug release at 9 hr)
Source Sum of squares df Mean square F value p value P>F Significance
Model 440.7568 9 48.97298 7.323789 0.007795 Significant
A-CH 254.5896 1 254.5896 38.07325 0.000458
B-GG 34.48651 1 34.48651 5.157373 0.057394
C-CC 11.95605 1 11.95605 1.787998 0.222986
AB 0.403225 1 0.403225 0.060301 0.813065
AC 20.7936 1 20.7936 3.109632 0.121196
BC 7.6729 1 7.6729 1.147463 0.319618
A2 79.29865 1 79.29865 11.85892 0.010783
B2 14.57065 1 14.57065 2.179005 0.183416
C2 22.8144 1 22.8144 3.411838 0.10722
Residual 46.80786 7 6.686836
Lack of fit 46.79038 3 15.59679 3569.06 2.61E-07 Significant
Pure error 0.01748 4 0.00437
Correlation total 487.5647 16
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Prepared factorial batches were also showed good percentage yield for 
batch C1, C2, C4, and C7 (91.20±1.22%, 93.83±2.14%, 95.12±2.15%, 
and 94.16±1.15%, respectively) show good result as compared with 
other batches (Table 9 and Fig. 6).
Drug entrapment of multiparticulate of ciprofloxacin
The prepared multiparticulate was evaluated for drug entrapment 
study. The % drug entrapment in all formulation was found to be 
good, i.e., above 60% (Table 10). The multiparticulate of trial batches 
ciprofloxacin C3a, C5a, C3b, and C5b (72.37±1.13%, 84.68±1.15%, 
79.31±1.15%, and 83.06±1.8%, respectively) formulation showed a 
higher entrapment efficiency, whereas the other formulations showed 
lesser entrapment than this formulation. This can be attributed to the 
polymer composition of chitosan:guar gum in 2:1 ratio (Fig. 7).
Prepared factorial batches of multiparticulate also show good % 
drug entrapment in the range of 60-80%. For batch C4 shows good 
% entrapment, i.e., 80.24±4.12% then the other formulation. From 
this data, it is clear that increase in polymer concentration, especially 
chitosan increases the entrapment of drug (Fig. 8).
Ex vivo mucoadhesion study of batches
The mucoadhesive properties of the multiparticulate were evaluated by 
ex vivo mucoadhesion study. After the intervals of 12 hrs, the weight of 
microspheres leached out was measured.
Form the trial batches, C5a and C5b (84.68±1.15 and 80.48±0.37, 
respectively) batches show better adhesion as compared to the 
others. From this result, we can conclude that increase in polymer 
concentration (especially chitosan) increases the adhesion of 
multiparticulate because of increase in molecular weight of chitosan 
and increased viscosity then guar gum. This data also reveal that there 
is no influence of coat composition on adhesion because both the 
batches shows similar result whether it is for 10% (low) coat or 15% 
coat composition (high) (Fig. 9).
Fig. 3: Swelling studies of multiparticulate of trial batch of 
ciprofloxacin
Table 7: Analysis of variance for response R4 (drug release at 12 hr)
Source Sum of squares df Mean square F value p value P>F Significance
Model 441.9632 9 49.10702 41.96248 2.88E-05 Significant
A-CH 132.0313 1 132.0313 112.8222 1.44E-05
B-GG 58.86125 1 58.86125 50.29758 0.000195
C-CC 12.005 1 12.005 10.2584 0.015006
AB 0.0361 1 0.0361 0.030848 0.865553
AC 0.3364 1 0.3364 0.287457 0.608462
BC 28.6225 1 28.6225 24.45824 0.001665
A2 106.4031 1 106.4031 90.92259 2.93E-05
B2 90.96381 1 90.96381 77.72957 4.88E-05
C2 22.8193 1 22.8193 19.49934 0.003097
Residual 8.19182 7 1.17026
Lack of fit 8.1009 3 2.7003 118.7989 0.00023 Significant
Pure error 0.09092 4 0.02273
Correlation total 450.155 16
Table 8: Analysis of variance for response R5 (drug release at 18 hr)
Source Sum of squares df Mean square F value p value P>F Significance
Model 155.25 9 17.25 146.6525 3.92E-07 Significant
A-CH 126.2461 1 126.2461 1073.293 6.39E-09
B-GG 6.283513 1 6.283513 53.41987 0.000162
C-CC 0.032512 1 0.032512 0.276408 0.615303
AB 0.0169 1 0.0169 0.143677 0.715888
AC 0.2601 1 0.2601 2.211265 0.180601
BC 0.001225 1 0.001225 0.010414 0.921578
A2 15.86716 1 15.86716 134.8962 7.91E-06
B2 2.771059 1 2.771059 23.55842 0.001848
C2 3.870322 1 3.870322 32.90391 0.000708
Residual 0.823375 7 0.117625
Lack of fit 0.818575 3 0.272858 227.3819 6.36E-05 Significant
Pure error 0.0048 4 0.0012
Correlation total 156.0734 16
Fig. 4: Swelling studies of multiparticulate of factorial batch of 
ciprofloxacin
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Table 9: Analysis of variance for response R6 (drug release at 24 hr)
Source Sum of squares df Mean square F value p value P>F Significance
Model 185.2627 9 20.58474 17.5134 0.000525 Significant
A-CH 28.99411 1 28.99411 24.66806 0.001625
B-GG 2.152812 1 2.152812 1.831603 0.218012
C-CC 0.2312 1 0.2312 0.196704 0.670779
AB 5.2441 1 5.2441 4.461656 0.072546
AC 1.500625 1 1.500625 1.276725 0.295735
BC 0.042025 1 0.042025 0.035755 0.855389
A2 123.3708 1 123.3708 104.9633 1.82E-05
B2 0.650312 1 0.650312 0.553282 0.481196
C2 15.93672 1 15.93672 13.55889 0.007836
Residual 8.227595 7 1.175371
Lack of fit 7.873075 3 2.624358 29.61027 0.003431
Pure error 0.35452 4 0.08863 17.5134 0.000525 Significant
Correlation total 193.4902 16
Table 10: Changes in body weight of Wistar male rat male rat 
during study






1 Group I 236.13±2.14 237.06±2.03 242.11±1.10
2 Group II 235.21±3.23 229.34±1.13 237.45±1.03
3 Group III 243.02±1.23 249.22±2.43 250.00±2.03
Each sample was analyzed in triplicate (n=3)
Fig. 5: Percentage yield of multiparticulate of trial batch of 
ciprofloxacin
Fig. 6: Percentage yield of multiparticulate of factorial batch of 
ciprofloxacin
Fig. 7: % drug entrapped of trial batches of ciprofloxacin
adhesion than the others. This data for factorial batches conclude that 
increase in polymer concentration increases the adhesion, and it is not 
affected by coat composition (Fig. 10).
In vitro drug release studies for batches of ciprofloxacin
In vitro dissolution study was conducted to understand in vitro 
drug release profile of coated multiparticulate. The purpose of 
this formulation was to avoid release of drug in gastric and upper 
intestinal region but to release the drug slowly in the lower part of the 
intestine maximizing drug concentration in the colon. Enteric-coated 
multiparticulate, coated with a coat composition of Eudragit S and L 
100 (10%, and 15%), showed no drug release in simulated gastric fluid 
up to 2 hrs indicating the intactness of the applied coat. Dissolution 
studies were continued for a further 4 hr period in simulated intestinal 
media showing relatively low drug release, i.e., up to 20-25%. Release of 
drug beyond 6 hrs in simulated colon fluid was varied substantial with 
over 95% release in 24 hrs for trial batches of ciprofloxacin; batch C5a 
(92.87±0.41) and C5b (90.42±0.43) shows better release as compared 
to others (Fig. 11).
For factorial batches, absorbance of sample of dissolution study was 
done after 6 hrs by consider the data from trial batches, i.e. negligible 
release (30%) of drug up to 6 hr. Analysis was done on samples of 9, 
12, 18, and 24 hrs. The results show that for ciprofloxacin batch C4 
shows maximum release of drug, i.e., 97.64±0.15%, compared to other 
formulations (Fig. 12).
It was interesting to observe low release profiles of coated 
multiparticulate in GIT. This could be due to the cross-linking of chitosan 
which did not disintegrate under the influence of colon enzymes and 
thus can be stated that the multiparticulate retained their integrity. The 
release could be by diffusion and/or by erosion of the multiparticulate 
matrix.
Release kinetics
The release rate constant was calculated from the slope of appropriate 
equations, and the correlation coefficient (R) was determined for all 
the formulations. The release profile and the entrapment efficiency of 
formulation of factorial batches C4 for, was found to be satisfactory in 
comparison to other formulation, the discussion on the kinetics of other 
formulations was not considered further.
In vitro drug release of C4 was best explained by Korsmeyer-Peppas 
equation with highest linearity R2=0.9979 followed by Higuchi’s 
equation, R2=0.9944 and first order R2=0.9811. This indicates that the 
drug was diffused from the polymeric matrix. The drug release was 
found to be closed to Higuchi kinetics which indicates that the drug 
diffuses at a comparatively slower rate as the distance of diffusion 
increases. Further, the value of “n” from Korsmeyer-Peppas equation 
for C4 (n=0.8054) indicates a purely relaxed controlled delivery which 
referred to as Case II transport. Occasionally, values of n>0.89 have 
been observed, which have been regarded as Super Case II kinetics. Our 
Factorial batches also show good adhesion, i.e. more than 68%. For 
ciprofloxacin factorial batches, batch C4 (90.23±2.02%) shows better 
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results clearly advocate the non-Fickian diffusion owing to the coupling 
of diffusion process with the mechanical response of the polymer 
chitosan and guar gum.
Factorial design data analysis
Experimental design analysis
Use of experimental design allows systematic optimization procedures 
which carried out by selecting an objective function, finding the most 
important or contributing factors, and investigating the relationship 
between responses and factors by the so-called RSM. Objective 
function for the present study was selected as maximizing the polymer 
concentration and polymer coating, i.e. coat composition efficiency 
while studying its effect on entrapment efficiency, mucoadhesion, and 
drug release at 9, 12, 18, and 24 hrs for ciprofloxacin.
Box-Behnken design was used to statistically optimize the processing 
parameters and evaluate the main effects, interaction effects, and 
quadratic effects of the processing parameters on the polymer 
concentration and enteric coating on formulations. A 3-factor, 3-level 
design was used to explore the quadratic response surfaces and for 
constructing second order polynomial models using design expert 
(Version 9.0.5.1, Stat-Ease Inc., Minneapolis, MN). The Box-Behnken 
design was specifically selected since it requires fewer runs than a 
central composite design, in cases of three or four variables. This cubic 
design is characterized by set of points lying at the midpoint of each 
edge of a multidimensional cube and center point replicates (n=1). 
A design matrix was constructed with 17 experimental runs, for which 
the linear computer-generated quadratic model for responses such as 
entrapment efficiency (R1), mucoadhesion (R2); drug release at 9 (R3), 
12 (R4), 18 (R5), and 24 (R6) was giving as:
R1= 79.49−0.0675*A 2.31875*B −0.10875*C−3.055*AB −0.16*AC 
0.1825*BC 2.32125*A2 −13.75125*B2 −4.04125*C2
R2= 87.218+5.5*A 2.44875*B 0.65375*C −3.28*AB −0.92*AC 
−0.3225*BC −2.24775*A2 −2.75525*B2 0.98475*C2
R3= 70.188+5.64125*A 2.07625*B 1.2225*C 0.3175*AB −2.28*AC 
−1.385*BC 4.33975*A2 −1.86025*B2 −2.32775*C2
R4= 79.106+4.0625*A 2.7125*B −1.225*C 0.095*AB 0.29*AC −2.675*BC 
5.027*A2 −4.648*B2 −2.328*C2
R5= 83.72+3.9725*A 0.88625*B −0.06375*C 0.065*AB −0.255*AC 
−0.0175*BC 1.94125*A2 −0.81125*B2 0.95875*C2
R6= 87.604+1.90375*A 0.51875*B −0.17*C −1.145*AB −0.6125*AC 
−0.1025*BC 5.413*A2 0.393*B2 1.9455*C2
For ciprofloxacin response R1, 79.49 is an intercept, and 2.31875, 
−0.10875, −3.055, −0.16, 0.1825, 2.32125, −13.75125, and −4.04125 
are regression coefficient computed from the observed experimental 
values of R1 from experimental runs; A, B, and C are the coded levels of 
independent variables. The terms AB, AC, BC, and A2, B2, C2 represent the 
interaction and quadratic terms, respectively. Same is for the responses 
R2, R3, R4, R5, and R6.
Independent variable studied was polymer concentration, i.e., chitosan 
(A), guar gum (B), and coat composition of Eudragit L and S 100 
(C). The dependent variables were the entrapment efficiency (R1), 
mucoadhesion (R2); drug release at 9 (R3), 12 (R4), 18 (R5), and 
24 (R6). The range of independent variables under study along with 
their low, medium, and high levels, which were selected based on the 
Fig. 8: % drug entrapped of factorial batches of ciprofloxacin
Fig. 9: Ex vivo mucoadhesion study of trial batches of ciprofloxacin
Fig. 10: Ex vivo mucoadhesion study of factorial batches of 
ciprofloxacin
Fig. 11: % cumulative release of batches of ciprofloxacin
Fig. 12: % cumulative release of factorial batches of ciprofloxacin
175
Asian J Pharm Clin Res, Vol 10, Issue 1, 2017, 167-185
 Rangari and Puranik 
results from preliminary experimentation. The polymer concentration, 
i.e., chitosan (A), guar gum (B), and coat composition of Eudragit L 
and S 100 (C) used to prepare the 17 experimental formulations. 
The polynomial equations can be used to draw a conclusion after 
considering the magnitude coefficient and the mathematical sign that 
the coefficient carries. A high positive or negative value in the equation 
represents that by making a minor change in the setting of that factor 
one may obtain a significant change in the dependent variable.
Statistical validity of the polynomials was established on the basis 
of ANOVA provision in the Design Expert Software. The level of 
significance was considered at >F<0.05. The best-fitting mathematical 
model was selected based on the comparison of several statistical 
parameters, including the CV, the multiple correlation coefficient (R2), 
the adjusted multiple correlation coefficient (adjusted R2), and the 
PRESS, provided by the software. PRESS indicates how well the model 
fits the data, and for the chosen model, it should be small relative to 
the other models under consideration. The 3D response surface graphs 
and the 2D contour plots were also generated by the Design Expert® 
Software. These plots are very useful to see interaction effects of the 
factors on responses.
Full and reduced model assessment for the dependent variables
The result of responses R1 to R6 was 95% for ciprofloxacin. All the 
responses observed for seventeen processing variables were fitted 
to various models using “Design Expert Software.” It was observed 
that the best-fitted models were quadratic. The values of R2, adjusted 
R2, predicted R2, SD, and %CV along with the regression equation are 
generated for each response. It was observed that the independent 
variable viz. A (chitosan) had a positive effect on drug release (R). Other 
independent variables, viz., B (guar gum) and C (coat composition) had 
a negligible effect (R) (Table 3).
Response R1 (entrapment efficiency) A negative “Pred R2” implies 
that the overall mean was a better predictor of your response than the 
current model. “Adeq Precision” measures the signal to noise ratio. A 
ratio >4 was desirable. Your ratio of 8.554 indicates an adequate signal. 
This model can be used to navigate the design space. Response R2 
(mucoadhesion) A negative “Pred R2” implies that the overall mean 
was a better predictor of your response than the current model. “Adeq 
Precision” measures the signal to noise ratio. A ratio >4 was desirable. 
Your ratio of 13.001 indicates an adequate signal. This model can be 
used to navigate the design space. Response R3 (drug release at 9 hr) A 
negative “Pred R2” implies that the overall mean was a better predictor 
of your response than the current model. “Adeq Precision” measures 
the signal to noise ratio. A ratio >4 was desirable. Your ratio of 9.775 
indicates an adequate signal. This model can be used to navigate the 
design space.
Response R4 (drug release at 12 hr): The “Pred R2” of 0.7118 was not 
as close to the “Adj R2” of 0.9584 as one might normally expect or a 
possible problem with your model and/or data. Things to consider are 
model reduction, response transformation, outliers, etc. All empirical 
models should be tested by doing confirmation runs. “Adeq Precision” 
measures the signal to noise ratio. A ratio >4 is desirable. Your ratio 
of 22.701 indicates an adequate signal. This model can be used to 
navigate the design space. Response R5 (drug release at 18 hr): The 
“Pred R2” of 0.9160 is in reasonable agreement with the “Adj R2” of 
0.9879, i.e. the difference is <0.2. “Adeq Precision” measures the signal 
to noise ratio. A ratio >4 is desirable. Your ratio of 41.267 indicates an 
adequate signal. This model can be used to navigate the design space. 
Response R6 (drug release at 24 hr): The “Pred R2” of 0.3461 is not 
as close to the “Adj R2” of 0.9028 as one might normally expect or a 
possible problem with your model and/or data. Things to consider are 
model reduction, response transformation, outliers, etc. All empirical 
models should be tested by doing confirmation runs. “Adeq Precision” 
measures the signal to noise ratio. A ratio >4 is desirable. Your ratio 
of 12.080 indicates an adequate signal. This model can be used to 
navigate the design space.
Statistical validation of the polynomial equations generated by design 
expert and estimation of the significance of the models was established 
on the basis of ANOVA provision of the software (Table 4).
For response R1 (entrapment efficiency), the model F value of 11.2627 
implies the model is significant. There is only a 0.21% chance that a 
“Model F value” this large could occur due to noise. Values of “p>F” 
<0.0500 indicate model terms are significant. In this case, B (guar 
gum), ++2+−, and C++2+− are significant model terms. Values >0.1000 
indicate the model terms are not significant. The “Lack of Fit F value” 
of 931.13 implies the lack of fit is significant. There is only a 0.01% 
chance that a “Lack of fit F value” this large could occur due to noise. 
The p values for response R1 (entrapment efficiency) represent that 
the linear contribution (A, B, and C) is a significant model. The values 
obtained for main effects of the independent variables from equation 
indicate that chitosan (A), guar gum (B), and coat composition have a 
positive effect on the response R1 (entrapment efficiency). From the 
figure 13 and 14 of the response curve of entrapment efficiency for 
multiparticulate, it is observed that as the guar gum (B) concentration 
at high level (1) increases entrapment efficiency of multiparticulate 
significantly. From the equation, they indicate that concentrations 
of chitosan (A) at medium level (0) were effective for response R1 
(entrapment efficiency). On the other hand, the coat composition at a 
low level (−1) is sufficient to reach the multiparticulate to the colon 
(Figs. 13 and 14).
For response R2 (mucoadhesion), the model F value of 10.24 implies 
the model is significant. There is only a 0.29% chance that a “Model 
F value” this large could occur due to noise. Values of “p>F” <0.0500 
indicate model terms are significant. In this case, A, B, AB, and B++2+− 
are significant model terms. Values >0.1000 indicate the model terms 
are not significant. If there are many insignificant model terms (not 
counting those required to support hierarchy), model reduction may 
improve your model. The “Lack of Fit F value” of 1762.57 implies the 
Lack of Fit is significant. There is only a 0.01% chance that a “Lack of 
Fit F value” this large could occur due to noise. In Table 19, p values 
for response R2 (mucoadhesion) represent that the linear contribution 
(A, B, and C) is the significant model term. The values obtained for 
main effects of the independent variables from equation indicate that 
chitosan (A) and guar gum (B) have a positive effect on the response 
R2 (mucoadhesion). From the Figs. 46 and 47 of the response curve of 
mucoadhesion for multiparticulate, it is observed that as the chitosan 
(A) concentration at high level (1) increases entrapment efficiency of 
multiparticulate increases significantly. From equation, they indicate 
that concentrations of guar gum (B) at medium level (0) are effective for 
response R2 (mucoadhesion). On the other hand, the coat composition 
at a low level (−1) is sufficient to reach the multiparticulate to colon 
(Figs. 15 and 16).
For response R3 (drug release at 9 hr), the model F value of 7.32 
implies the model is significant. There is only a 0.78 % chance 
that a “Model F value” this large could occur due to noise. Values 
of “p>F” <0.0500 indicate model terms are significant. In this case, 
A and A++2+− are significant model terms. Values >0.1000 indicate 
the model terms are not significant. If there are many insignificant 
model terms (not counting those required to support hierarchy), 
model reduction may improve your model. The “Lack of Fit F 
value” of 3569.06 implies the lack of fit is significant. There is only 
a 0.01% chance that a “Lack of Fit F value” this large could occur 
due to noise. In Table 20, p values for response R3 (drug release at 
9 hr) represent that the contribution (A, B, and C) is significant to 
model term. The values obtained for main effects of the independent 
variables from equation indicate that chitosan (A) at high level (1) 
have positive effect on the response R3 (drug release at 9 hr). From 
the Figs. 48 and 49 of the response curve of drug release at 9 hr 
for multiparticulate, it is observed that high (1) concentration of 
chitosan (A) releases the drug at 9 hr significantly. From equation, 
they indicate that concentrations of guar gum (B) at medium level 
(0) are effective for response R3 (drug release at 9 hr). On the other 
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hand, the coat composition at a low level (−1) is sufficient to reach 
the multiparticulate to colon (Figs. 17 and 18).
For Response R4 (drug release at 12 hr), the model F value of 41.96 
implies the model is significant. There is only a 0.01 % chance that a 
“Model F value” this large could occur due to noise. Values of “p>F” 
<0.0500 indicate model terms are significant. In this case, A, B, C, BC, 
A++2+−, B++2+−, and C++2+− are significant model terms. Values 
>0.1000 indicate the model terms are not significant. If there are many 
insignificant model terms (not counting those required to support 
hierarchy), model reduction may improve your model. The “Lack of Fit 
F value” of 118.80 implies the lack of fit is significant. There is only a 
0.02% chance that a “Lack of Fit F value” this large could occur due to 
noise. The p values for response R4 (drug release at 12 hr) represent 
that the contribution of (A, B, and C) is significant to model term. The 
values obtained for main effects of the independent variables from 
equation indicate that chitosan (A) at high level (1) have a positive effect 
on the response R4 (drug release at 12 hr). From the figure 17 and 18 
of the response curve of drug release at 9 hr for multiparticulate, it is 
observed that high (1) concentration of chitosan (A) releases the drug 
at 12 hr significantly. From equation, they indicate that concentrations 
of guar gum (B) at medium level (0) are effective for response R4 (drug 
release at 12 hr). On the other hand, the coat composition at a low level 
(−1) is sufficient to reach the multiparticulate to colon (Figs. 19 and 20).
For Response R4 (drug release at 18 hr), the model F value of 146.65 
implies the model is significant. There is only a 0.01 % chance that 
a “Model F Value” this large could occur due to noise. Values of 
“p>F”<0.0500 indicate model terms are significant. In this case, A, 
B, A++2+−, B++2+−, and C++2+− are significant model terms. Values 
>0.1000 indicate the model terms are not significant. If there are many 
insignificant model terms (not counting those required to support 
hierarchy), model reduction may improve your model. The “Lack of Fit 
F value” of 227.38 implies the lack of fit is significant. There is only a 
0.01% chance that a “Lack of Fit F value” this large could occur due to 
noise. TheC p values for response R5 (drug release at 18 hr) represent 
Fig. 13: 3D response curve for R1
Fig. 14: Contour plot for R1
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Fig. 15: 3D response curve for R2
Fig. 16: Contour plot for R2
Fig. 17: 3D response curve for R3
that the contribution of (A, B and C) is significant to model term. The 
values obtained for main effects of the independent variables from 
equation indicate that chitosan (A) at high level (1) have a positive effect 
on the response R5 (drug release at 18 hr). From the figure 19 and 20 
of the response curve of drug release at 9 hr for multiparticulate, it is 
observed that high (1) concentration of chitosan (A) releases the drug 
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Fig. 18: Contour plot for R3
Fig. 19: 3D response curve for R4
Fig. 20: Contour plot for R4
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Fig. 21: 3D response curve for R5
Fig. 22: Contour plot for R5
at 18 hr significantly. From equation, they indicate that concentrations 
of guar gum (B) at medium level (0) are effective for response R5 (drug 
release at 18 hr). On the other hand, the coat composition at a low level 
(−1) is sufficient to reach the multiparticulate to colon (Figs. 21 and 22).
For response R6 (drug release at 24 hr), the model F value of 17.51 implies 
the model is significant. There is only a 0.05% chance that a “Model 
F value” this large could occur due to noise. Values of “p>F” <0.0500 
indicate model terms are significant. In this case, A, A++2+−, and C++2+− 
are significant model terms. Values >0.1000 indicate the model terms are 
not significant. If there are many insignificant model terms (not counting 
those required to support hierarchy), model reduction may improve 
your model. The “Lack of Fit F value” of 29.61 implies the lack of fit is 
significant. There is only a 0.34% chance that a “Lack of Fit F value” this 
large could occur due to noise. The p values for response R6 (drug release 
at 24 hr) represent that the contribution of (A, B, and C) is significant to 
model term, and the linear contribution (C) is the nonsignificant model 
term. The values obtained for main effects of the independent variables 
from equation indicate that chitosan (A) at high level (1) have a positive 
effect on the response R6 (drug release at 24 hr). From the Figure. 19 
and 20 of the response curve of drug release at 24 hr for multiparticulate, 
it is observed that high (1) concentration of chitosan (A) releases the drug 
at 24 hr significantly. From equation, they indicate that concentrations 
of guar gum (B) at medium level (0) are effective for response R6 (drug 
release at 24 hr). On the other hand, the coat composition at low level (−1) 
is sufficient to reach the multiparticulate to colon (Figs. 23 and 24).
Advanced studies on optimized batch of multiparticulates
XRD study
The powder XRD patterns for the pure ciprofloxacin and their polymeric 
composites are given in Fig. 25. The data obtained for the multiparticulate 
of ciprofloxacin in terms of the lattice spacing and the relative line 
intensities. Most of the characteristic lines in the diffraction patterns 
were generally prominent and sharp. Proper sample preparation helps 
attain accurate peak positions for qualitative analysis. If the sample 
surface is irregular or if it is displaced from the focusing circle, peak 
locations and intensities will vary. All the high-intensity peaks (relative 
intensity) observed in the XRD pattern of the pure drug ciprofloxacin 
were compared. The pure drugs were found to show similar XRD 
patterns as that with the polymeric composites. Identification of a 
structure from its powdered diffraction pattern is based on the position 
of peaks and their relative intensities. Each XRD pattern is characterized 
by the 2θ and the relative intensities (I/I0) of strongest peaks.
DSC studies of optimized multiparticulates
The thermograms of the pure drug characteristic, sharp endothermic peak 
at 288.90°C for ciprofloxacin, also the thermogram of physical mixtures 
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of optimized formulation shows characteristic, sharp endothermic peaks 
at 297.81°C for physical mixture of ciprofloxacin. This concludes that the 
peaks were associated with the melting point of the drug and indicates the 
amorphous nature of the drug. The DSC thermogram of polymers (Figs. 27 
and 28), pure drug ciprofloxacin (Fig. 26), and their physical mixture of 
polymer of optimized batches were shown in the following Fig. 29.
Morphological results with SEM
Morphology of multiparticulate was examined by SEM. The smooth 
surface of such multiparticulate as seen by SEM might be due to this 
complete homogeneity of drug and polymers and coating. The outer 
surface of the multiparticulate was smooth and dense this is because 
of coating of mulatiparticulate using coat composition of Eudragit 
S and L 100, whereas the internal surface was porous. The shell of 
the multiparticulate also showed some porous structure. It may be 
caused by the evaporation of the solvent entrapped within the shell of 
multiparticulate after forming a smooth and dense skin layer. Some of 
the multiparticulate showed a dented surface structure (Figs. 30-32).
IR interpretations for drug polymer interaction in formulation
IR spectroscopy was used as means of studying drug-excipients 
compatibility and confirmed by comparing undisturbed structure of IR 
spectra of pure ciprofloxacin (Fig. 33), polymers (Figs. 34 and 35), and 
physical mixture of optimized batch (Fig. 36) which indicated no drug-
excipients interaction.
In vivo gamma scintigraphy study
The gamma scintigraphy study in rat showed that the multiparticulate 
were intact in the hostile environment of the stomach at 1 and 
15 minutes duration, but whenever, they reached to the colonic region 
they stars degradation due to the presence of anaerobic bacteria 
present in colon (Fig. 37).
Histopathology evaluation
During the experimental period (84 days), the inflammatory agent 
exposed rats (Group II) exhibited a significantly low gain in body weight 
and growth rate throughout the experimental period as compared to 
Group I and Group III. To the Group III (multiparticulates containing 
250 mg/kg/day of ciprofloxacin), was administered which shows 
significantly increased in weight gain when compared with Group II 
(Table 10).
Histopathological observations of the colon from control group animals 
Group I showed the normal structure of the villi (Figs. 38 and 39). 
Fig. 24: Contour plot for R6
Fig. 23: 3D response curve for R6
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2, 4, 6, trinitrobenzene sulfonic acid administered colons showed 
inflammatory changes as the presence of inflammatory cells in 
submucosal area and distortion of villi (Group II) (Figs. 40 and 41). 
Treatment with ciprofloxacin multiparticulate (Group III) has shown 
reduction in the infiltration of inflammatory cells and villi appeared 
normal (Fig. 42).
CONCLUSION
Targeted drug delivery into the colon is highly desirable for local treatment 
of a variety of bowel diseases such as ulcerative colitis, Crohn’s disease, 
amebiosis, colonic cancer, local treatment of colonic pathologies, and 
systemic delivery of protein and peptide drugs. Specifically, mucoadhesive 
multiparticulate systems appear to be an exploitable delivery system for 
colon release of drugs, and hence, we have selected this topic for our 
Fig. 25: Comparative graph of ciprofloxacin, chitosan, guar gum, and polymer composite of optimized batch
Fig. 26: Differential scanning colorimeter of pure drug 
ciprofloxacin
Fig. 27: Differential scanning colorimeter of polymer chitosan
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research. For this, we have selected antibiotic agent ciprofloxacin. These 
categories of drug generally used to cure diseases related to colon. To 
prepare mucoadhesive colon targeted multiparticulate system, we have 
used natural polymers such as chitosan and guar gum together with 
Eudragit S and L 100 for coating of multiparticulate. The drugs and 
excipient were subjected to compatibility testing before formulation, 
i.e., IR, DSC, and XRD. The result of drug excipient compatibility testing 
reveals that there is no sign of incompatibility in peaks for respective 
analysis.
The preliminary trial batches were prepared and evaluated, out of 
which, for C3a, C5a, C3b, and C5b shows good entrapment efficiency, 
swelling index, ex vivo mucoadhesion, and in vitro drug release 
than other formulation. Factorial batches were also prepared using 
“Design Expert Software,” and formulations were also evaluated 
for same as like for preliminary trials. For formulated factorial 
batches, of ciprofloxacin C4 batch shows good entrapment efficiency, 
swelling index, ex vivo mucoadhesion, and in vitro drug release 
and was considered as an optimized formulation and further 
subjected to advanced studies such as SEM, in vivo evaluation 
(gamma scintigraphy), and histopathological study. The results of 
Fig. 28: Differential scanning colorimeter of polymer guar gum
Fig. 29: Differential scanning colorimeter of optimized batch of 
ciprofloxacin
Fig. 30: Scanning electron microscopy of multiparticulate with 
coating
Fig. 31: Scanning electron microscopy of multiparticulate without 
coating
Fig. 32: Scanning electron microscopy of optimized batch of 
ciprofloxacin
Fig. 33: IR of pure drug ciprofloxacin
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Fig. 34: IR of polymer chitosan
Fig. 35: IR of polymer guar gum
Fig. 36: Physical mixture of optimized batch of ciprofloxacin
Fig. 37: In vivo gamma scintigraphy on Wistar male rat male rat using multiparticulate without drug
the study clearly indicate that there is a great potential in delivery 
of ciprofloxacin to the colonic region. The study showed that the 
manipulation of polymer concentration and coat composition 
influence particle size of multiparticulate, flow property, drug 
release profile, etc. From the above study, it concluded that high 
concentration of chitosan together with guar gum retard the drug 
release, may be due to the cross-linking of chitosan which did not 
disintegrate under the influence of colon enzymes and also coating 
with Eudragit S and L 100 composition prevents its release in GIT and 
helps to target the drug in colon. Formulation C4 for ciprofloxacin was 
the best formulation for controlling the drug release to the colon. The 
efficiency of ciprofloxacin as a nonsteroidal anti-inflammatory drug 
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was also evaluated successfully with 2, 4, 6, trinitrobenzene sulfonic 
acid colitis in rat model. The formulation C4 confirmed to serve as a 
new drug delivery system to treat inflammatory bowel disease.
Gamma scintigraphy and histological study of optimized formulation 
C4 for ciprofloxacin showed that the formulation can specifically deliver 
the drug to the site of action; the animals treated with this formulation 
had an improvement in pathology and may be useful for the treatment 
of inflammatory bowel disease and colon cancer.
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